Equities

Kalvista Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.90
  • Today's Change0.83 / 7.50%
  • Shares traded1.81m
  • 1 Year change+74.74%
  • Beta0.8681
Data delayed at least 15 minutes, as of Mar 28 2024 18:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.

  • Revenue in USD (TTM)0.00
  • Net income in USD-108.30m
  • Incorporated2004
  • Employees118.00
  • Location
    Kalvista Pharmaceuticals Inc55 Cambridge Pkwy Ste 901ECAMBRIDGE 02142-1234United StatesUSA
  • Phone+1 (857) 999-0075
  • Fax+1 (302) 531-3150
  • Websitehttps://www.kalvista.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Harrow Inc130.19m-24.41m450.17m315.00--6.33--3.46-0.7448-0.74483.992.010.55464.556.13413,311.10-10.40-10.86-12.14-12.7169.5570.75-18.75-15.352.610.04450.7223--46.9525.77-73.30--143.88--
Alto Neuroscience Inc0.00-32.74m451.11m63.00---------1.28-1.280.001.41------0.00--------------------0.2133---100.00---201.62------
Aeon Biopharma Inc0.00-28.71m452.60m10.00----103.55---0.7727-0.77270.00-3.28------0.00------------------0.5686--------5.54------
OraSure Technologies, Inc.405.47m53.66m453.11m638.008.521.056.071.120.72040.72045.475.860.87483.157.31635,536.1011.580.723813.110.821244.2546.9413.231.138.57--0.00180.004.6417.41413.1782.2010.18--
PepGen Inc0.00-78.63m455.87m64.00--3.10-----3.30-3.300.004.550.00----0.00-43.62---48.51--------------0.00-------13.78------
Inozyme Pharma Inc0.00-71.17m456.49m59.00--3.25-----1.39-1.390.002.270.00----0.00-41.86-45.00-45.82-48.90------------0.2417-------6.13--2.85--
Ocugen Inc0.00-75.53m456.57m84.00--7.82-----0.3242-0.32420.000.22770.00----0.00-79.11-83.81-91.61-96.15-------446,793.90----0.0453-------39.38--74.43--
Caribou Biosciences Inc34.48m-102.07m462.41m158.00--1.23--13.41-1.45-1.450.46754.170.0856--17.14218,208.90-25.33---27.24-------296.05-----19,343.170.00--148.91---2.66------
Larimar Therapeutics Inc0.00-36.95m463.51m42.00--3.90-----0.8416-0.84160.001.860.00----0.00-33.24-42.22-36.56-47.14------------0.00-------4.51--8.71--
Arbutus Biopharma Corp18.14m-72.85m466.68m73.00--4.17--25.73-0.4386-0.43860.10930.62410.1068--11.60248,506.80-42.88-52.62-51.22-58.11-----401.57-537.81----0.00---53.5125.00-4.89---2.40--
Kalvista Pharmaceuticals Inc0.00-108.30m467.02m118.00--4.32-----3.14-3.140.002.560.00----0.00-68.23-33.56-75.55-36.55-------941.88----0.00-------12.83---3.47--
Akebia Therapeutics Inc194.62m-51.93m468.99m167.00------2.41-0.2778-0.27781.04-0.15720.65122.224.891,165,407.00-17.37-37.42-28.19-56.0078.7669.13-26.68-82.251.03-7.648.46---33.46-1.3044.89------
iTeos Therapeutics Inc12.60m-112.64m472.05m157.00--0.8205--37.48-3.15-3.150.352216.050.0177--2.8280,222.93-15.845.84-16.817.02-----894.3522.09----0.000.00-95.29---216.54--68.45--
Altimmune Inc279.00k-78.47m477.65m52.00--3.12--1,712.01-1.57-1.570.00552.850.0014--0.36985,365.39-40.05-41.05-43.09-44.12-----28,124.01-1,013.75----0.00---101.54--12.75---5.40--
Entrada Therapeutics Inc129.01m-6.69m482.18m159.00--1.98--3.74-0.2543-0.25433.867.250.3578----811,402.50-1.85---2.47-------5.18------0.00------92.93------
Marinus Pharmaceuticals Inc30.99m-141.41m483.59m165.00--28.81--15.61-2.63-2.630.57660.30720.1441.556.11187,812.10-65.70-49.64-77.53-57.7693.76---456.31-518.964.01-14.970.8132--21.63---613.59--7.47--
Data as of Mar 28 2024. Currency figures normalised to Kalvista Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

43.76%Per cent of shares held by top holders
HolderShares% Held
Tang Capital Management LLCas of 31 Dec 20233.44m8.28%
Adage Capital Management LPas of 15 Feb 20242.85m6.84%
Suvretta Capital Management LLCas of 31 Dec 20232.68m6.46%
BlackRock Fund Advisorsas of 31 Dec 20232.05m4.94%
Saturn V Capital Management LLCas of 31 Dec 20231.81m4.35%
The Vanguard Group, Inc.as of 31 Dec 20231.75m4.22%
Jefferies Investment Advisers LLCas of 31 Dec 20231.08m2.60%
Driehaus Capital Management LLCas of 31 Dec 20231.03m2.47%
Citadel Advisors LLCas of 31 Dec 2023783.70k1.89%
Dimensional Fund Advisors LPas of 31 Dec 2023716.96k1.73%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.